Search

everythinglearnresearchcommunity

for

Search:↓

The user had a hair transplant and is using oral minoxidil and finasteride but seeks advice for treating the crown area. They are looking for additional recommendations for non-transplanted areas.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

Scientists found hidden stem cells that might reactivate hair growth. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

User "hairplsrn" shares their hair loss journey, trying various treatments like finasteride, minoxidil, and dutasteride, but experiencing worsening hair loss. They decide to get a partial frontal hair system and continue medication, while others offer support and advice on staying on medication and focusing on overall confidence.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.

The conversation discusses whether gt20029 could cure complete baldness, mentioning verteporfin as a realistic treatment. Other treatments like Minoxidil, finasteride, and RU58841 are implied to be less promising.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.

Hair loss treatments like spironolactone often require lifelong use to maintain results. Stopping the medication can lead to increased testosterone levels and potential hair loss.

The conversation is about a user experiencing a tingling sensation and redness on their scalp, possibly related to hair loss treatments. Suggestions include using Nizoral shampoo and consulting a dermatologist, while the user mentions using oral finasteride.

A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

The user experienced good hair growth results using a combination of finasteride, minoxidil, and a topical formulation, but faced temporary numbness as a side effect. They manage this by microdosing oral finasteride and minoxidil and using the topical formulation sparingly.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

The conversation is about a user sharing their positive progress with hair regrowth using oral minoxidil, biotin, finasteride, and other supplements. The user also mentions using a HIMS oral fin/min combo and receives advice and encouragement from others.

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

The user has been using topical minoxidil with tretinoin for 9 months without much regrowth and suspects finasteride is responsible for any improvement. They are inquiring about tests to determine response to topical minoxidil and seeking advice on switching to oral minoxidil, including potential side effects and monitoring requirements.

The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.

High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.

Hair loss discussion mentions ineffective treatments like Nutrafol and low-level laser therapy sold by transplant clinics. Trust in hair restoration doctors questioned due to promoting these treatments.

A 23-year-old with hair loss uses finasteride, minoxidil, and other treatments, considering adding dutasteride due to hairline recession. They seek advice on dutasteride's effectiveness and sourcing.

Transitioning from finasteride to dutasteride for hair loss, with suggestions to either slowly transition or frontload dutasteride. The user is also using minoxidil, nizoral, needling, and LLLT.

The user is using finasteride, minoxidil, and microneedling for hair regrowth and has noticed some improvement after nine weeks. They report no significant side effects and plan to continue the treatment to see further results.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.